目的 觀察分清化濁膠囊對阿霉素腎病大鼠的影響及其可能的作用機(jī)制。方法 將雄性SD大鼠隨機(jī)分為6組（對照組，模型組，陽性對照組，分清化濁膠囊低、中、高劑量組），除對照組外，其余各組大鼠采用尾iv阿霉素法制成阿霉素腎病大鼠模型，第一次尾iv阿霉素（4 mg/kg）1周后，第二次iv阿霉素（3.5 mg/kg）。造模成功后，對照組和模型組ig生理鹽水，陽性對照組ig黃葵膠囊混懸液；其余治療組ig分清化濁膠囊混懸液。每日一次，療程4周。觀察大鼠一般情況，在給藥前、給藥7、14、21、28 d測定24 h尿蛋白定量，末次給藥后，測定大鼠血清總蛋白（TP）、白蛋白（ALB）、總膽固醇（TC）、三酰甘油（TG）、血尿素氮（BUN）、肌酐（Cr），并觀察大鼠腎臟病理變化。結(jié)果 治療前，與對照組比較，各治療組尿蛋白定量有顯著差異（P＜0.01），說明造模成功；陽性組、分清化濁膠囊各劑量組均能顯著降低尿蛋白（P＜0.01）。與模型組比較，分清化濁膠囊高、中劑量能升高TP、ALB水平（P＜0.01）。分清化濁膠囊高、中劑量對TG及TC有降低作用（P＜0.01）。各治療組對腎功能指標(biāo)BUN、Cr無明顯影響。各治療組腎臟病變程度較模型組有明顯減輕。結(jié)論 分清化濁膠囊可以顯著降低阿霉素腎病大鼠尿蛋白、TC、TG；明顯升高阿霉素腎病大鼠TP、ALB水平，減輕腎臟病理損害。

Objective To study the effect and the possible mechanism of Fenqing Huazhuo Capsule (FHC) on Adrianycin-induced nephrosis rats. Methods Sixty SD rats were randomly divided into six groups (control, model, positive control, low-, mid-, and high-dose FHC groups), all the rats except those in the control group were tail-intravenously injected with Adriamycin to establish the animal model, in 4 mg/kg for the first time and one week later in 3.5 mg/kg for the second time. After the model establishment, rats in the control and model groups were ig administered with physiological saline, rats in the positive control group were ig administered with Huangkui Capsule suspension, and rats in the other treatment groups were ig administered with FHC suspension, once daily for four weeks. The situation of the rats was observed, 24 h urinary protein was determinated before administration; On the day 7, 14, 21, and 28 after the last administration, the total protein (TP), albumin (Alb), total cholesterol (TC), triacylglycerol (TG), blood urea nitrogen (BUN), and creatinine (CR) in serum were determined after the last adminnistration,and the pathological changes in kidney were observed. Results Before the treatment, the urine protein of each treatment group was significantly different (P < 0.01) compared with the control group; the urinary protein could be significantly reduced (P < 0.01) in the positive control and FHC treatment groups. Compared with the model group, the contents of TP and ALB in the high- and mid-dose FHC groups could be increased (P < 0.01). The levels of TG and TC in the high- and mid-dose FHC groups could be reduced. There was little effect on the index of renal function in the treatment groups, which indicated that the pathological changes of kidney could be significantly reduced. Conclusion Each dosage of FHC could decrease the contents of the urinary protein, TC, and TG, increase the contents of TP and ALB in serum, and lighten the pathological lesion of kidney.

國際合作計劃（2009DFA31350）